-
Product Insights
NewGlutamate Receptor Ionotropic NMDA 2 – Drugs In Development, 2024
The Glutamate Receptor Ionotropic NMDA 2 pipeline drugs market research report outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Respiratory, and Dermatology which include indications of Schizophrenia, Post-Traumatic Stress Disorder (PTSD), Cardiac Arrest, Orthostatic Hypotension, Idiopathic Pulmonary Fibrosis, Chronic Cough, and Burns. It...
-
Product Insights
NewGlutamate Receptor Ionotropic NMDA 2B – Drugs In Development, 2024
The Glutamate Receptor Ionotropic NMDA 2B pipeline drugs market research report outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Respiratory, and Dermatology which include indications of Post-Traumatic Stress Disorder (PTSD), Neurodegenerative Diseases, Cardiac Arrest, Orthostatic Hypotension, Idiopathic Pulmonary Fibrosis, Chronic Cough, and Burns....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Dementia Associated With Alzheimer's Disease Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Mild Cognitive Impairment report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Mild Cognitive Impairment Drug Details: Dalzanemdor (SAGE-718) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Huntington Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Huntington Disease Drug Details: Dalzanemdor (SAGE-718) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-1020 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GM-1020 in Major Depressive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GM-1020 in Major Depressive Disorder Drug Details: GM-1020 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radiprodil in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Radiprodil in Tuberous Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radiprodil in Tuberous Sclerosis Drug Details: Radiprodil is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radiprodil in Seizures
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Radiprodil in Seizures report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radiprodil in Seizures Drug Details: Radiprodil is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-10508 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-10508 in Major Depressive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-10508 in Major Depressive Disorder Drug Details: XW-10508 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-Ketamine in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-Ketamine in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-Ketamine in Cluster Headache Syndrome (Cluster Headache) Drug...